NCT00909961View on ClinicalTrials.gov

A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years

PHASE3CompletedINTERVENTIONAL
Enrollment

118

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 16, 2011

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

Zoledronic acid

Trial Locations (6)

Unknown

Novartis Investigational site, Ankara

Novartis Investigative site, Antalya

Novartis Investigational site, Istanbul

Novartis Investigative site, Izmir

Novartis Investigative site, Kayseri

Novartis Investigative site, Konya

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY